BWXT - BWXT Medical to supply radioisotope Ac-225 to Bayer for radionuclide therapies

BWX Technologies (NYSE:BWXT) said its unit BWXT Medical signed an agreement to supply high-purity radioisotope Actinium-225 (Ac-225) to Bayer (OTCPK:BAYRY) (OTCPK:BAYZF) for radionuclide therapies. Bayer will buy Ac-225 from BWXT Medical at pre-determined prices and the companies expect the supply to begin later this year, BWX said in a June 27 press release. BWX said radioisotope Ac-225 is a powerful radioisotope used in targeted alpha therapies (TATs). This treatment field combines Ac-225 with specific tumor-seeking targeting moieties, which deliver alpha radiation directly to tumors.

For further details see:

BWXT Medical to supply radioisotope Ac-225 to Bayer for radionuclide therapies